Asthma therapeutics: Key market research findings
- The Americas dominates the market geographically
- Inhalation is the largest ROA segment
- Key vendors – AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GSK, and Merck
Technavio’s market research analysts predict the global market for asthma therapeutics to grow at a CAGR of around 5% between 2016 and 2020. The growth of the market is spurred by the huge market for mAbs. mAbs is expected to have a high uptake for the treatment of asthma owing to the development of target specific drugs. mAbs blocking IgE are specifically approved for the treatment of allergic asthma. During 2015, the global asthma therapeutics market was dominated by the Americas with a market share of more than 48%. Healthcare reforms coupled with the high prevalence of asthma in the region will fuel the market’s growth in this region during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of the asthma therapeutics segments based on the route of administration.
“Vendors in the market are currently working on the development of drugs and delivery devices as per end-user requirements. Vendors are also investing heavily in R&D activities to design and develop innovative inhalers and nebulizers that are compact, portable, patient-friendly, and provide accurate results. Advancements pertaining to inhalers such as sensors, use of smartphones, and tablets that can track and record the drug treatment dose have provided an interface between the physicians and patients,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
During 2015, the inhalation segment accounted for around 78% of the overall market revenue to become the key revenue generating segment of the global market. In this ROA, the precise amount of drug is administered using delivery devices such as inhalers. The onset of action of the drug is quick with systemic and local effect.
The key vendors in the global asthma therapeutics market include AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GSK, and Merck. Owing to the presence of several well established and small scale vendors, this market appears to be highly fragmented. Key players such as GSK, AstraZeneca, Boehringer Ingelheim, F.Hoffmann-La Roche, and Merck have a great product portfolio and account for the majority of revenue shares. The competition among vendors is intense and the leading vendors have also started acquiring smaller regional vendors to increase their share of the market. The coming years will witness a number of mergers and acquisitions and innovative product launches, which will further intensify the competitive environment in the market.
A more detailed analysis is available in the Technavio report, Global Asthma Therapeutics Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
